Second-line therapy for advanced non-small-cell lung cancer

Research output: Contribution to journalArticle

Abstract

Over the past three decades, progress has been made in the first-line treatment of advanced non-small-cell lung cancer (NSCLC). Current recommendations include combination chemotherapy with or without targeted therapy. Despite these advances, the majority of patients relapse after initial treatment. Many of these patients are eligible for second-line therapy, which has prompted significant clinical research in this area. In 1999, docetaxel became the first drug approved by the US Food and Drug Administration for the treatment of patients with advanced NSCLC in the second-line setting. In 2004, two additional agents, pemetrexed and erlotinib, also received approval, giving patients three options for second-line treatment. Many promising new drugs and drug combinations are currently under investigation.

Original languageEnglish (US)
Pages (from-to)243-247
Number of pages5
JournalCurrent oncology reports
Volume8
Issue number4
DOIs
StatePublished - Jul 1 2006

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Second-line therapy for advanced non-small-cell lung cancer'. Together they form a unique fingerprint.

  • Cite this